At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Bexarotene +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
In Brief
A Phase 1 clinical trial evaluating Bexarotene and Questionnaire Administration for Breast Atypical Ductal Hyperplasia and 4 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs that are called rexinoids, and it may reduce the incidence of breast tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartJun 2018
Primary CompletionAug 2021
Study CompletionMar 2022
TodayJul 2026
First PostedOct 27, 2017
Enrollment StartJun 15, 2018
Primary CompletionAug 3, 2021
Study CompletionMar 25, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 8.7 years ago
Interventions
Bexarotenedrug
Given topically
Questionnaire Administrationother
Ancillary studies